0001810417-26-000012.txt : 20260511 0001810417-26-000012.hdr.sgml : 20260511 20260511160509 ACCESSION NUMBER: 0001810417-26-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260507 FILED AS OF DATE: 20260511 DATE AS OF CHANGE: 20260511 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sullivan Christopher Ryan CENTRAL INDEX KEY: 0001810417 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37590 FILM NUMBER: 26963107 MAIL ADDRESS: STREET 1: C/O CERECOR INC. STREET 2: 400 E. PRATT STREET, SUITE 606 CITY: BALTIMORE STATE: MD ZIP: 21202 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avalo Therapeutics, Inc. CENTRAL INDEX KEY: 0001534120 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 450705648 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1500 LIBERTY RIDGE DRIVE STREET 2: SUITE 321 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 410-522-8707 MAIL ADDRESS: STREET 1: 1500 LIBERTY RIDGE DRIVE STREET 2: SUITE 321 CITY: WAYNE STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: Cerecor Inc. DATE OF NAME CHANGE: 20111102 4 1 form4-05112026_040503.xml X0609 4 2026-05-07 0001534120 Avalo Therapeutics, Inc. AVTX 0001810417 Sullivan Christopher Ryan false C/O AVALO THERAPEUTICS, INC. 1500 LIBERTY RIDGE DRIVE, SUITE 321 WAYNE PA 19087 false true false false Chief Financial Officer 1 Common Stock 2026-05-07 4 M 0 18606 9.88 A 19029 D Common Stock 2026-05-07 4 S 0 18606 24.1222 D 423 D Stock Option (Right to Buy) 9.88 2026-05-07 4 M 0 18606 0 D 2034-08-13 Common Stock 18606 168094 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025. The reported securities were sold in multiple transactions at prices ranging from $24.05 to $24.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date. /s/ Christopher Sullivan 2026-05-11